Avastin optimum dosing schedule defined

Article

When using bevacizumab to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.

When using bevacizumab (Avastin) to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.

Dr Luis Arias of the Department of Ophthalmology at the Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain and colleagues segregated patients into two groups: the LD group received bevacizumab monthly for three months followed by as-needed dosing, and the PRN group received a single injection of bevacizumab followed by as-needed dosing. Doctors considered that another injection of bevacizumab was necessary if any of the following factors were present: macular oedema (either persistent or recurrent), pigment epithelial detachment or subretinal fluid.

At six months, no ocular or systemic side effects were observed in either group. In the LD group, mean visual acuity increased by 13.7 letters, and 36% of subjects had gained 15 or more letters; mean foveal thickness decreased by 91.3 µm. In comparison, in the PRN group, mean visual acuity increased by only 4.6 letters, and just 12% of subjects had gained 15 or more letters; mean foveal thickness decreased by 48.2 µm.

Thus the researchers concluded that an LD regime was a more effective and equally safe treatment protocol when compared with PRN dosing.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.